Community Research and Development Information Service - CORDIS


TRIMAGE Report Summary

Project ID: 602621
Funded under: FP7-HEALTH
Country: Italy

Periodic Report Summary 2 - TRIMAGE (A dedicated trimodality (PET/MR/EEG) imaging tool for schizophrenia)

Project Context and Objectives:
Schizophrenia is a severe mental disorder, characterized by profound disruptions in thinking, affecting language, perception, and the sense of self. It often includes psychotic experiences, such as hearing voices or delusions. Schizophrenia disorders manifest themselves early in life during very active life periods of education and productive work and can impair functioning through the loss of an acquired capability to earn a livelihood, or the disruption of studies. This causes a high social and economic burden on European societies. In most of the cases, if correctly diagnosed, schizophrenia can be treated, and people who are affected can lead a productive life and be integrated in society. Schizophrenia is usually studied using a translational approach: psychological, social and biological parameters are acquired and analyzed together, but the early diagnosis still remains a critical challenge. Currently, there is a strong need for an imaging tool that facilitates the diagnosis of schizophrenia early during development. It is important to stress that precise and early diagnosis cannot be achieved with a single measurement. Additionally, an off-line combination of data acquired separately could be insufficient, because several correlated patient-specific signals may vary over time. As a consequence, the full integration of different diagnostic modalities into a seamless clinical tool is necessary for the application of multiparametric measurements in all schizophrenia patients and especially for prodromic patients. Such a tool is not available today.
The main objectives of this project are two-fold: (a) to build and optimise an integrated diagnostic solution including a molecular imaging tool based on simultaneous Positron Emission Tomography (PET), Magnetic Resonance (MR) and Electroencephalography (EEG), and (b) to validate the new tool with specific biomarkers for detecting characteristic patterns in asymptomatic and at-risk patients and for monitoring disease follow-up during drug therapy.

The goals of this project will be achieved by the scientific and technological developments in both the medical and technological fields. These developments will be carried out following three strongly correlated S&T sub-objectives:

Sub-objective 1 (clinical) - Find new biomarkers and define a suitable multimodal paradigm with already available PET, MR, EEG and PET/MR systems that could provide clinical evidence on the feasibility of advanced schizophrenia diagnosis. Specific biomarkers that synergistically define the disease signature are still unavailable and need to be developed.

Sub-objective 2 (technological) - Construct and test an optimized cost-effective trimodality imaging instrument (brain PET/MR/EEG) for diagnosis, monitoring and follow-up of schizophrenia disorders. This leads to the optimization of well established imaging modalities and their full integration in a novel dedicated trimodal instrument. In combination with the new set of biomarkers, the brain PET/MR/EEG scanner will represent a complete turn-key solution for the early diagnosis of schizophrenia.

Sub-objective 3 (clinical) - Validate the trimodal imaging device with regard to the results and the clinical data obtained during the development of the sub-objective 1.

The final aim of the project is to create a trimodal, cost-effective imaging tool consisting of PET/MR/EEG using cutting edge technology with performance beyond the state of the art. The tool is intended for broad distribution so as to enable effective early diagnosis of schizophrenia and possibly other mental disorders.

Project Results:
The recruitment of patients and healthy volunteers required for the defining of the suitable paradigm to be validated on the trimodal imaging PET/MR/EEG device started in 2015 at TUM (20 patients and 20 healthy volunteers) and in late 2016 at Jülich (20 patients and 20 healthy volunteers) following the approval by the respective Ethics Committee and Radiation Protection Committee for both institutions. The experimental procedure at TUM was based on the 3T mMR tomograph and the tracer used was [18F]-Dopa; 39 subjects have been scanned so far (24 patients and 15 controls). The analysis of the imaging data is still on-going. The experimental procedure at Jülich will be performed on the available PET/MR/EEG scanner.The loudness dependence of auditory evoked potentials (LDAEP) has been identified as a good marker and the tracer to be used is [11C]-ABP688. The recruitment of patients and healthy volunteers at Aachen/Jülich has started: the clinical study will be conducted during the first 6 months of 2017. The MRI paradigm has been completely defined at both institutions.

As for the PET/MR/EEG scanner the PET system has been fully designed. The PET ring has an inner radius of 157.2 mm and is composed by 18 sectors on a cylindrical geometry. Each sector is made of 3 modules, axially juxtaposed, for a total axial length of about 165 mm. A Monte Carlo model of the TRIMAGE scanner using the Monte Carlo toolkit GATE was developed. The PET image reconstruction was developed to accommodate the TRIMAGE scanner geometry. The simulation gives a sensitivity of the scanner of about 7% at the center of the FOV and a spatial resolution of about 2 mm (FWHM), i.e., well beyond the PET performance of the available 3T PET/MR systems.

The design of the TRIROC ASIC, the DAQ electronics and the mechanics of the PET scanner has also been completed and they are under test or in advanced construction. MR compatibility assessment has been done on individual PET components and on the relevant parts of the system. The entire PET tomograph will be assembled and fully tested in Pisa to be brought to RS2D for final testing inside the 1.5T magnet.

As for the MR, the full specifications of the 1.5T magnet were decided and the order was placed with the selected manufacturer (SSI,USA) in 2015. The “alpha magnet” has been delivered to RS2D and tested up to 1T. A commercial coil has been used for testing the alpha magnet so as to start the integration of the gradient coils and of all the electronics. The development of the coil interface board, the gradient controller and the gradient temperature monitoring system is also under completion. Preparatory work on the development of MRI sequences (including MP-RAGE, EPI, and EPIK) has started on a preclinical PET/MR system. MR attenuation correction for PET was developed based on external attenuation maps given from specific subjects. The final 1.5T magnet for TRIMAGE, the so-called “beta magnet”, will be delivered at RS2D site early 2017.

All the steps have been completed to identify the site for the final installation of the TRIMAGE scanner at Jülich. A RF-shielded room (approximately 4 m x 3 m x 3 m) has been prepared for this purpose. In preparation for the clinical trial, we are working for a combined BfArM and ethics application. Two main documents are in preparation: the Clinical Investigator Brochure (under final review) and the Investigator Brochure (still at the draft stage). The complete application will be submitted in summer 2017.

A project logo, a brochure set and documentation templates were delivered. The TRIMAGE website is up and running and it is being maintained with the latest updates coming from the consortium. The number of TRIMAGE publications increased substantially, as project results became available. As of today, the publication list accounts for 11 scientific journal articles, 4 conference presentations and 2 other presentations.

A series of workshop on PET/MR has been co-organised yearly from 2014 to 2018. Papers from these workshops have been or will be published on special issues of International Journals. Two training schools on PET/MR have been organized: the first one in Jülich in March 2016 and the second will run in Lisbon in May 2017. A dedicated workshop on "Schizophrenia and other mental disorders" is planned for June 2017 in Pisa.

Potential Impact:
Schizophrenia is a chronic disorder that affects about 7 per 1000 of the adult population. Several expert reports clearly demonstrate the economic impact of schizophrenia and the market potential for a device as proposed by TRIMAGE. Schizophrenia is the second most costly disease in terms of the average cost per patient with an average cost being higher than that for cancer and stroke. The earlier the treatment is initiated, the more effective it is. However, a significant number of people with schizophrenia do not receive any medication or are not yet receiving timely, adequate treatment. The WHO estimates that more than 50% of persons with schizophrenia do not receive appropriate care.

Diagnoses of mental disorders are often based on the clinical expertise of the treating physician. This is true also for the treatment: whether the patient responds to a given treatment can currently be assessed only by monitoring the clinical course (2-6 weeks), a long time for the patient and his/her family and for the health system. The trimodality imaging (PET/MR/EEG) device that we are developing in this project aims to give the clinicians an effective tool for the diagnosis and choice of treatment for mental health disorders such as schizophrenia. Early diagnosis of schizophrenia could provide the opportunity to intervene earlier and, thus, to avert the trajectory to psychosis.

The final product of the TRIMAGE project, i.e., the PET/MR/EGG brain scanner will have a strong technological impact, not limited to the field of schizophrenia and brain disorders. More innovations will result from side tasks of the project. Some of the expected outcomes, which will have a technological impact, are:

i)-Progress in SiPM fabrication and readout,

ii)-New methods for improved DoI information and sensitivity optimization in PET,

iii)-Improved algorithms for PET/MR attenuation correction and image quantification,

iv)-Design, integration and performance evaluation of a PET/MR compatible insert,

v)-Realistic GATE simulations using computational brain phantoms,

vi)-Identification of Schizophrenia biomarkers, through a multimodal approach,

vii)-Realization of a targeted clinical study using the recently introduced PET/MR scanners.

The TRIMAGE project is based in an emerging area of multimodal brain imaging applications, where new kinds of expertise are being introduced. In order to reinforce the future generation of scientists for continuing development in these specialised emerging fields, TRIMAGE partners participate in the following actions:

i)-Training of young scientists via lectures at universities, and education of young researchers during practical training sessions as well as seminars.

ii)-Practical skills have been developed by supervising diplomas and doctoral theses.Where appropriate, exchanges have been organised for PhD/Post doc students between TRIMAGE partners.

iii) Organization of scientific schools and workshops.

In parallel to more general external communication, TRIMAGE aims to include education within medical programs to help open up a new generation of clinicians to this technology at national and European levels, in particular with psychiatrists, clinicians and doctors. Partners will look to participate in topical workshops and seminars aimed at stressing the interdisciplinary character of biomedicine with particular reference to the emerging area of multimodal imaging and personalised therapeutic treatments via biomarkers identification.

List of Websites:


Sandra Masi, (Administrative Responsible)
Tel.: +39 0502214639
Fax: +39 0502214634


Life Sciences
Record Number: 197890 / Last updated on: 2017-05-16